Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Craddock

Showing results (91-100 of 165) with videos related to

Pageof 17
Sort By:
Lancet (London, England)|June 7, 2005
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationKarl S Peggs, Ann Hunter, Rajesh Chopra, et al.
BMJ Open|March 29, 2024
Protocol for a mixed-methods study to develop and feasibility test a digital system for the capture of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor T-cell (CAR-T) therapies (the PRO-CAR-T study)Sarah E Hughes, Christel McMullan, Olalekan Lee Aiyegbusi, et al.
Blood Advances|October 26, 2021
Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantationRachael Hough, Andre Lopes, Pip Patrick, et al.
Leukemia Research|July 6, 2019
Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid diseaseFrancesca A M Kinsella, Charlotte F Inman, Amy Gudger, et al.
Blood|January 31, 2013
Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMTEsa Jantunen, Ariane Boumendil, Herve Finel, et al.
Eclinicalmedicine|June 13, 2025
Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus studySarah E Hughes, Foram Khatsuria, Christel McMullan, et al.
Blood Advances|January 4, 2018
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemiaLynn Quek, Paul Ferguson, Marlen Metzner, et al.
Leukemia|August 1, 2019
Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMTMaria H Gilleece, Myriam Labopin, Bipin N Savani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 13, 2015
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA TrialCharles Craddock, Nadira Jilani, Shamyla Siddique, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignanciesKatharine Branson, Rajesh Chopra, Panagiotis D Kottaridis, et al.
Pageof 17

Showing results (91-100 of 165) with videos related to

Sort By:
Pageof 17
Lancet (London, England)|June 7, 2005
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationKarl S Peggs, Ann Hunter, Rajesh Chopra, et al.
BMJ Open|March 29, 2024
Protocol for a mixed-methods study to develop and feasibility test a digital system for the capture of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor T-cell (CAR-T) therapies (the PRO-CAR-T study)Sarah E Hughes, Christel McMullan, Olalekan Lee Aiyegbusi, et al.
Blood Advances|October 26, 2021
Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantationRachael Hough, Andre Lopes, Pip Patrick, et al.
Leukemia Research|July 6, 2019
Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid diseaseFrancesca A M Kinsella, Charlotte F Inman, Amy Gudger, et al.
Blood|January 31, 2013
Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMTEsa Jantunen, Ariane Boumendil, Herve Finel, et al.
Eclinicalmedicine|June 13, 2025
Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus studySarah E Hughes, Foram Khatsuria, Christel McMullan, et al.
Blood Advances|January 4, 2018
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemiaLynn Quek, Paul Ferguson, Marlen Metzner, et al.
Leukemia|August 1, 2019
Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMTMaria H Gilleece, Myriam Labopin, Bipin N Savani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 13, 2015
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA TrialCharles Craddock, Nadira Jilani, Shamyla Siddique, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignanciesKatharine Branson, Rajesh Chopra, Panagiotis D Kottaridis, et al.
Pageof 17